Alison Moskowitz, MD
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alison Moskowitz, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:40 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05010005 · A Study of Ruxolitinib and Duvelisib in People With LymphomaMemorial Sloan Kettering Cancer Center · active not recruiting · T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia · principal investigator
- Ph2NCT04960618 · Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary SyndromeMemorial Sloan Kettering Cancer Center · active not recruiting · Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome · principal investigator
- Ph2NCT03728972 · Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal TypeMemorial Sloan Kettering Cancer Center · active not recruiting · NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis) · principal investigator
- Ph2NCT03618550 · Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaMemorial Sloan Kettering Cancer Center · recruiting · Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma · principal investigator
- Ph2NCT03587844 · Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsMemorial Sloan Kettering Cancer Center · active not recruiting · Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome · principal investigator
- Ph2NCT03179917 · Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin LymphomaMemorial Sloan Kettering Cancer Center · active not recruiting · Hodgkin Lymphoma · principal investigator
- Ph2NCT03179930 · Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasMemorial Sloan Kettering Cancer Center · active not recruiting · Lymphoma, Relapsed, Refractory · principal investigator
- Ph1/Ph2NCT03033914 · A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Memorial Sloan Kettering Cancer Center · active not recruiting · Hodgkin Lymphoma · principal investigator
- Ph2NCT02974647 · Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaMemorial Sloan Kettering Cancer Center · recruiting · Lymphoma · principal investigator
- Ph1/Ph2NCT02429375 · Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin LymphomaMemorial Sloan Kettering Cancer Center · completed · Hodgkin Lymphoma · principal investigator
- N/ANCT02106611 · Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) SurvivorsMemorial Sloan Kettering Cancer Center · completed · Hodgkin Lymphoma Survivor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.